Straits Times Index
3,101.83 +11.52 (+0.37%) Nikkei
33,194.03 -237.48 (-0.71%) Hang Seng
16,753.99 -76.31 (-0.45%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
41,443.59 +1,993.07 (+5.05%) CMC Crypto 200
802.76 +11.20 (+1.41%)
CStone Pharmaceuticals (2616.HK)
| Previous close | 2.220 |
| Open | 2.210 |
| Bid | 2.070 x 0 |
| Ask | 2.080 x 0 |
| Day's range | 2.060 - 2.210 |
| 52-week range | 1.620 - 6.220 |
| Volume | |
| Avg. volume | 3,519,730 |
| Market cap | 2.657B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.690 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- PR Newswire
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd., a subsidiary of 3SBio Inc. ("3SBio", HKEX: 1530) for an anti-PD-1 antibody nofazinlimab in mainland China.
- PR Newswire
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the anti-PD-L1 antibody sugemalimab (Cejemly®) for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal an
